Protagenic Therapeutics Files S-1 for Potential Offering

TL;DR

Protagenic Therapeutics just filed an S-1, looks like they're prepping for a public stock offering.

AI Summary

Protagenic Therapeutics, Inc. filed an S-1 registration statement on December 20, 2024, to register an unspecified number of securities. The company, formerly known as Atrinsic, Inc., is incorporated in Delaware and headquartered in New York City. This filing indicates a potential offering of new securities to the public.

Why It Matters

This S-1 filing signals Protagenic Therapeutics' intention to raise capital through a public offering, which could impact its stock price and future development plans.

Risk Assessment

Risk Level: medium — As an S-1 filing, it indicates a potential new offering, which carries inherent market and execution risks for investors.

Key Numbers

• 333-283949 — SEC File Number (Identifies the specific SEC registration)
• 06-1390025 — IRS Number (Company's Employer Identification Number)

Key Players & Entities

• Protagenic Therapeutics, Inc. (company) — Registrant
• Atrinsic, Inc. (company) — Former company name
• 20241220 (date) — Filing date
• 149 FIFTH AVENUE (address) — Principal executive offices
• NEW YORK (location) — Principal executive offices city
• DE (location) — State of incorporation
• Garo Armen (person) — Executive Chairman

FAQ

Key Financial Figures

• $0.0001 — 5 shares of our common stock, par value $0.0001 per share, which are comprised of (i) 1
• $0.642 — rted sale price of our common stock was $0.642 per share. We may amend or supplement
• $250 million — on stock held by non-affiliates exceeds $250 million as of the end of that year’s seco
• $100 million — quarter and our annual revenue exceeds $100 million during such completed fiscal year, or (
• $700 m — on stock held by non-affiliates exceeds $700 million, regardless of our annual revenue
• $5.36 — at a weighted average exercise price of $5.36 per share; and 942,566 shares of comm
• $19.47 — at a weighted average exercise price of $19.47 per share. Except as otherwise indica
• $34,749,473 — ions, and has an accumulated deficit of $34,749,473. Based on its cash resources and positi
• $5,000,497 — es since we began operations, including $5,000,497 and $3,555,505 for the years ended Dece
• $3,555,505 — an operations, including $5,000,497 and $3,555,505 for the years ended December 31, 2023 a

Filing Documents

• forms-1.htm (S-1) — 637KB
• ex5-1.htm (EX-5.1) — 28KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 14KB
• ex5-1_001.jpg (GRAPHIC) — 11KB
• ex5-1_002.jpg (GRAPHIC) — 1KB
• forms-1_001.jpg (GRAPHIC) — 6KB
• ex23-1_001.jpg (GRAPHIC) — 23KB
• ex23-1_002.jpg (GRAPHIC) — 92KB
• 0001493152-24-050846.txt ( ) — 868KB

USE OF PROCEEDS

USE OF PROCEEDS 35 MARKET FOR OUR COMMON STOCK 35 DIVIDEND POLICY 35 SELLING SECURITY HOLDERS 36

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 40 PLAN OF DISTRIBUTION 42 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 44 LEGAL MATTERS 44 EXPERTS 44 WHERE YOU CAN FIND ADDITIONAL INFORMATION 44 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 45 3 You should read this prospectus and any applicable prospectus supplement before making an investment in the securities of Protagenic Therapeutics, Inc. See “Where You Can Find More Information” for more information. You should rely only on the information contained in this prospectus or a prospectus supplement. The Company has not authorized anyone to provide you with different information. This document may be used only in jurisdictions where offers and sales of these securities are permitted. You should assume that information contained in this prospectus, or in any prospectus supplement, is accurate only as of any date on the front cover of the applicable document. Our business, financial condition, results of operations and prospects may have changed since that date. Unless otherwise noted in this prospectus, “Protagenic Therapeutics,” “Protagenic,” “the Company,” “we,” “us,” “our” and similar terms refer to Protagenic Therapeutics, Inc. Smaller Reporting Company - Scaled Disclosure Pursuant to Item 10(f) of Regulation S-K promulgated under the Securities Act of 1933, as amended (the “Securities Act”), as indicated herein, we have elected to comply with the scaled disclosure requirements applicable to “smaller reporting companies,” including providing two years of audited financial statements. 4 PROSPECTUS SUMMARY This summary highlights some information from this prospectus. It may not contain all the information important to making an investment decision. You should read the following summary together with the more detailed information regarding our Compan

View Full Filing

View this S-1 filing on SEC EDGAR